After Gambro AB was acquired in 2006 by EQT IV and Investor AB, Gambro (dialysis), CaridianBCT (blood technology) and the clinics business Gambro Healthcare were separated. CaridianBCT was thereafter managed as an independent company.
During EQT’s and Investor’s ownership, R&D investments were significant leading to CaridianBCT strengthening its position in the important growth areas of Pathogen Reduction and Whole Blood Processing.
- CountryUnited States
- FundEQT IV
The roll-out of several new products like the Spectra Optia Apheresis System and the Quantum Cell Expansion System during the ownership period will be important future growth drivers.
In 2011, EQT IV signed an agreement to sell CaridianBCT to the Japanese medical technology company Terumo Corporation for a total enterprise value of USD 2,625 m. CaridianBCT was at the time of the sale a world leading global provider of technology, products and services in automated blood collection, therapeutic systems, whole blood processes and pathogen reduction technologies.